No Credit Check Payday Loans
ALL BOOKS
Seeds

Pharmacology

Substances
Overdose

JoomlaWatch Agent

Visitors hit counter, stats, email report, location on a map, SEO for Joomla, Wordpress, Drupal, Magento and Prestashop

JoomlaWatch Users

JoomlaWatch Visitors



54% United States  United States
11.3% United Kingdom  United Kingdom
5.9% Australia  Australia
5.6% Canada  Canada
3.3% Philippines  Philippines
2.2% Kuwait  Kuwait
2.1% India  India
1.6% Germany  Germany
1.5% Netherlands  Netherlands
1.1% France  France

Today: 176
Yesterday: 310
This Week: 1539
Last Week: 2303
This Month: 5351
Last Month: 5638
Total: 24116


Use of GHB as a medicinal product (EMEA) PDF Print E-mail
User Rating: / 0
PoorBest 
Reports - EMCDDA Report on the risk assessment of GHB
Written by Richard Dennis   

As part of the preparation for the risk assessment of GHB, the European
Agency for the Evaluation of Medicinal Products (EMEA) asked for information
on the national situation of this product in terms of authorisation and
therapeutic value.

According to the responses received, GHB is authorised only in four countries:
in Italy and Austria for alcohol craving, and in France and in Germany
as an anaesthetic. In Germany it was put on the market before the German
Medicines Act came into force in 1978. Sales figures were not provided but
it can be assumed that they are low. GHB is subject to restricted prescription
in France and is regulated as a psychotropic substance in Italy.

 

Our valuable member Richard Dennis has been with us since Monday, 20 February 2012.

Show Other Articles Of This Author